The $4 billion acquisition is now cleared in the US, Germany, Austria, and South Africa.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.
Trichomonas is a nonviral sexually transmitted disease caused by infection with the protozoan parasite Trichomonas vaginalis.
Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.
The firm's reagents and disposables business was the biggest gainer, with a 12 percent revenue increase in the quarter.
Longhorn Vaccines and Diagnostics' one-step reagent for sample collection and transport enhanced M. tuberculosis detection on the Xpert MTB/RIF assay.
The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.